KORU Medical Systems, Inc. (KRMD): Entry into a Material Definitive Agreement
KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10 2 ex_10-1.htm AMENDMENT NO. 1 TO AMENDED & RESTATED MANUFACTURING & SUPPLY AGREEMENT Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND THE EXC
How this was made
The 30-second read
Why it matters
The amendment extends the agreement to 2031, updates 2026 product pricing via a new exhibit, and modifies payment terms and an annual true-up process—potentially affecting KRMD’s revenue recognition timing and margin profile.
Market read
This is a contract-terms update (term extension, pricing exhibit for 2026, payment-term reduction, and annual true-up mechanics) disclosed via SEC filing; however, key numeric inputs are redacted.
What to watch
Traders should focus on whether the Net payment-term change and the true-up mechanism shift risk between KORU and Command; the direction can’t be inferred from redacted values.
Background
The 8-K reports Item 1.01: entry into a material definitive agreement via Amendment No. 1 to an Amended and Restated Manufacturing and Supply Agreement between KORU Medical Systems and Command Medical Products.
Ticker impact
KORU (KRMD) amended its manufacturing and supply agreement, extending the term through Dec. 31, 2031 and updating 2026 pricing/payment terms.
Likely modest near-term impact; direction depends on whether revised pricing and Net terms improve KRMD economics versus prior agreement.
The filing discloses term extension and changes to pricing/payment mechanics, but key financial figures are redacted ([***]), limiting ability to quantify margin or cash-flow impact.
Market effects
May signal stability/continuity in medical device manufacturing supply arrangements, but no sector-wide regulatory or demand signal is provided.
No clear regional market linkage beyond the parties’ locations.
No explicit international expansion, tariffs, or cross-border regulatory change mentioned.
Counterpoint
Because the most material economics (pricing/true-up formula inputs) are redacted, the market may treat this as routine contract housekeeping rather than a value-creating change.
Key entities
- public_companyKORU Medical Systems, Inc.
Subject of the 8-K; entered Amendment No. 1 to its manufacturing and supply agreement.
- counterpartyCommand Medical Products, LLC
Counterparty to the manufacturing and supply agreement amendment.
